Amphastar Pharmaceuticals (AMPH) Non-Current Debt (2013 - 2026)

Amphastar Pharmaceuticals' Non-Current Debt history runs 14 years deep, the most recent figure standing at $609.8 million for Q1 2026.

• On a quarterly basis, Non-Current Debt rose 0.98% year-over-year to $609.8 million in Q1 2026; TTM through Mar 2026 was $609.8 million, a 0.98% increase from a year earlier, with the FY2025 full-year figure at $608.7 million, up 1.18% from the prior year.
• Non-Current Debt held at $609.8 million in Q1 2026 per AMPH's latest filing, from $608.7 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $638.2 million in Q3 2023 and bottomed at $72.8 million in Q4 2022.
• The 5-year median for Non-Current Debt is $594.0 million (2024), against an average of $441.3 million.
• Across the five-year window, Non-Current Debt jumped 762.31% in 2023 and retreated 6.54% in 2024, its largest moves.
• Year by year, Non-Current Debt stood at $72.8 million in 2022, then surged by 709.43% to $589.6 million in 2023, then advanced by 2.04% to $601.6 million in 2024, then advanced by 1.18% to $608.7 million in 2025, then gained by 0.17% to $609.8 million in 2026.
• Per Business Quant, the three latest AMPH Non-Current Debt figures stand at $609.8 million (Q1 2026), $608.7 million (Q4 2025), and $608.6 million (Q3 2025).